HEPHA-440
Solid Tumors (e.g., Osteosarcoma)
PreclinicalActive
Key Facts
About HEPHAISTOS-Pharma
HEPHAISTOS-Pharma is a private, preclinical-stage biotech tackling the major challenge of non-responsive 'cold' tumors in oncology. The company has developed a proprietary platform of systemic, detoxified TLR4 agonist immunotherapies designed to broadly activate the innate immune system against cancer. With €18.1M in seed and non-dilutive funding, a strong scientific founding team, and an orphan drug designation for its lead candidate in osteosarcoma, HEPHAISTOS is advancing towards first-in-human trials expected in 2027.
View full company profile